Integrative Research Associates — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$606	1
2024	Research	$53,663	5
2023	Research	$158,140	24
2022	Research	$226,936	193
2021	Research	$339,571	175
2020	Research	$309,335	178
2019	Research	$259,888	77

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $761,171 608 payments
Novartis Pharmaceuticals Corporation $513,779 28 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $39,037 5 payments
Boehringer Ingelheim International GmbH $31,953 10 payments
Amgen Inc. $2,200 2 payments

Studies the money was for Research payments · program years 2019–2025

Ex9536-4388 $760,240 537 payments
A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $124,665 3 payments
Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial to Determine Impact on Serious Events After Myocardial Infarction Paradise Mi $89,154 4 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $87,991 6 payments
A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An ""Inclisiran First"" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/DL) Despite Receiving Maximally Tolerated Statin Therapy (Victorion-Initiate) $63,875 1 payment
Empagliflozin for prevention of HHF and death after an AMI $54,182 11 payments
A Randomized, Multicenter, Open-Label Trial Comparing the Effectiveness of An Inclisiran First Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (?70 MG/D $54,097 1 payment
A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging in Patients With Chronic Heart Failure With Preserved Ejection Fraction $20,457 2 payments
A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $17,575 1 payment
Empagliflozin for prevention of HHF and death afte $16,808 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.